BioSpace News Archive

Immunoprecipitation Market Size to Reach USD 922.26 Million in 2028; CAGR of 5.2%, Says Reports And Data

Increasing research programs in the life sciences industry and technological advancements in immunoprecipitation techniques are supporting market growth.

January 19, 2022
·
7 min read
Drug Development

Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

A second Phase 3 trial evaluating Dupixent® in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease, met its primary and key secondary endpoints, showing it significantly reduced itch and skin lesions compared to placebo at 24 weeks in this investigational setting.

January 19, 2022
·
17 min read
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Alligator Bioscience announced the initiation a sponsored research collaboration to study biomarker data from Alligator’s OPTIMIZE-1 study with the University of Pennsylvania’s Pancreatic Cancer Research Center.

January 19, 2022
·
2 min read
Business

Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming

Altos Labs™ launched as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming.

January 19, 2022
·
10 min read
Biotech Bay

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced it has formally contracted with DCN Dx, a leading international developer of point-of-care diagnostics, and provider of comprehensive product development services.

January 19, 2022
·
7 min read
Policy

BioInvent: The FDA Grants Orphan Drug Designation to BI-1206 for the Treatment of Follicular Lymphoma

BioInvent International AB announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma.

January 19, 2022
·
3 min read
Policy

FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo.

January 19, 2022
·
17 min read
Business

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

Pharmaceutical leader brings over two decades of drug discovery and development in immunology and oncology.

January 19, 2022
·
3 min read
Business

WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE

Willow Biosciences Inc. is pleased to announce the results of its in vitro analysis and the first to be reported topical clinical study on cannabigerol (“CBG”).

January 19, 2022
·
6 min read
Drug Development

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA’s lead product candidate, EPI-7386.

January 19, 2022
·
6 min read